Yusuke Shono

Background

About Yusuke Shono

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a “two-edeged” swords; this treatment has preferable strong graft-versus-tumor effects (GVT) to cure diseases while at the same time this causes graft-versus-host disease (GVHD) that could lead to the adverse prognoses of treated patients. As a hematologist I observed many of the complications including GVHD after allo-HSCT, and also a researcher elucidated the effects of GVHD on hematopoiesis/hematopoietic niche, I keep on pursuing my research in this field of transplantation immunology trying to reveal the detailed mechanisms of GVHD and GVT. After joining MSKCC in 2011, I have been focusing attention on a network hub controlling immunity, inflammation, and cancer. We have small molecule c-Rel inhibitor compounds in our hands and by utilizing these compounds in vivo and in vitro, we observed effective suppression of c-Rel resulting in improved GVHD while preserving GVT activity. Intestinal damages are also important to initiate/sustain GVHD, so my projects also include models using knock-out mice of specific genes relevant to intestinal immune homeostasis. Recent projects also focus on gut microbiota. The ultimate goal is to develop promising methods to improve clinical outcomes of allo-HSCT.[Seminars and Extramural Invited Presentations (Recent)] Nov, 2018 “Gut microbiota injury in allogeneic hematopoietic stem cell transplantation”, The 23rd Annual Congress of APBMT, Taipei, Taiwan Apr, 2019 “Microbiota in allogeneic hematopoietic stem cell transplantation”, China Cancer Immunotherapy and Targeting Therapy Conference & Gaobo Medical Annual Meeting, Beijing, China [Honors and Awards] Fellowship Award from the Uehara Memorial Foundation (2011-2013) ASH Abstract Achievement Award (2012, 2013 and 2014) ASBMT Best Abstract Award (2013, 2014, and 2015)[Previous Private Research Support] Lymphoma Research Foundation, Post-Doctoral Fellowship (2013-2015) ASBMT, New Investigator Award (2015-2017)